Essential tremor (ET) is a prevalent movement disorder characterized by involuntary and rhythmic shaking, particularly affecting the hands and arms. The debilitating nature of this condition can significantly impede daily activities and diminish the quality of life for those affected. Previous treatments have often been inadequate and come with considerable side effects, highlighting the urgent need for innovative therapeutic strategies. Ketamine, traditionally used in surgical settings due to its anesthetic properties, has recently gained attention as a potential treatment for various neurological and psychiatric conditions.

The research by Ilaghi et al. builds upon the premise that ketamine may offer neuroprotective effects, especially in the context of neuroinflammation and neuronal damage. The team utilized a rodent model induced with harmaline to simulate essential tremor, thereby allowing for a controlled assessment of motor and cognitive outcomes post-ketamine administration. In this experimental setup, the behavioral responses of the subjects were meticulously observed following the administration of subanesthetic doses of ketamine.

One of the remarkable findings of this study is the observable improvement in motor performance in treated subjects compared to those that received a placebo. The administration of ketamine appeared to reduce the frequency and intensity of tremors in the harmaline-induced model, suggesting a significant modulatory effect on tremor-related motor deficits. This outcome aligns with previous studies that hinted at ketamine’s potential to influence motor functions, raising questions about the underlying mechanisms at play.

The exploration of Lingo-1, a protein implicated in neuronal signaling and inflammation pathways, served as a focal point in this research. Elevated expressions of Lingo-1 have been correlated with various neurodegenerative processes, making it a compelling target for therapeutic intervention. The results from Ilaghi’s study demonstrated a reduction in Lingo-1 levels among subjects treated with ketamine, hinting at a possible pathway through which ketamine could exert anti-inflammatory and neuroprotective effects in the context of essential tremor.

In tandem with Lingo-1, the inflammatory pathways of the brain were closely scrutinized. Ketamine’s influence on pro-inflammatory cytokines presents a novel area of investigation. The findings suggested that the subanesthetic doses of ketamine could lead to decreased levels of certain inflammatory markers, further supporting the theory that ketamine has a multi-faceted impact on neuroinflammatory processes. This aspect is particularly significant given the emerging understanding that chronic inflammation may heavily contribute to the pathophysiology of essential tremor and other related disorders.

Cognitive outcomes were also assessed as part of the study, providing a comprehensive view of ketamine’s potential as a therapeutic agent. Anxiety and cognitive deficits often accompany movement disorders, and addressing these co-morbidities is crucial for improving overall patient outcomes. The results indicated improvements in cognitive flexibility and anxiety levels within the group receiving ketamine treatment, opening avenues for its application beyond motor symptoms.

As researchers delve deeper into the potential use of ketamine in treating essential tremor, the pharmacological nuances come to light. Ketamine is known to function predominantly as an NMDA receptor antagonist, with implications for glutamatergic signaling in the brain. This unique action could redefine therapeutic approaches in neurology, as altering glutamate transmission might pave the way for innovative interventions that target not only tremor symptoms but also chronic pain and depressive disorders frequently seen in patients with essential tremor.

The ethical implications surrounding off-label ketamine use, however, cannot be overlooked. While its therapeutic potential expands, careful consideration is warranted regarding its administration outside of traditional settings. The study by Ilaghi et al. showcases the promising horizons in exploring existing medications for new therapeutic applications, but it also emphasizes the need for continuing clinical trials and regulatory examination.

Furthermore, the research draws attention to the growing body of evidence regarding the benefits of precision medicine in neurological disorders. Individual variations in response to treatment could significantly affect outcomes, suggesting that personalized approaches may be the future of interventions like ketamine. Tailoring treatment plans based on genetic and biological markers could enhance efficacy and limit adverse effects, culminating in better patient care.

In summary, the groundbreaking findings from Ilaghi and colleagues catalyze a re-evaluation of ketamine’s role in neurotherapeutics, particularly concerning movement disorders such as essential tremor. The interplay between its effects on motor, cognitive, and inflammatory pathways presents a promising frontier in understanding and potentially treating debilitating neurological conditions. As further research unfolds, the implications of these findings may resonate throughout the field, ushering in a new era of treatment modalities that could improve the lives of countless individuals grappling with essential tremor and similar disorders.

This comprehensive exploration reaffirms the importance of continued investigation into established drugs for novel applications. The journey of ketamine from an anesthetic to a prospective treatment for essential tremor signifies a crucial paradigm shift in how we approach neurological disorders, marking an exhilarating time for neuroscientific research.

Subject of Research: Effects of subanesthetic dose of ketamine on motor and cognitive outcomes of harmaline-induced essential tremor model

Article Title: Effects of subanesthetic dose of ketamine on motor and cognitive outcomes of harmaline-induced essential tremor model: a focus on Lingo-1 and inflammatory pathways

Article References:

Ilaghi, M., Pirmoradi, Z., Esmaili, Z. et al. Effects of subanesthetic dose of ketamine on motor and cognitive outcomes of harmaline-induced essential tremor model: a focus on Lingo-1 and inflammatory pathways.
BMC Neurosci 26, 49 (2025). https://doi.org/10.1186/s12868-025-00966-4

Image Credits: AI Generated

DOI: 10.1186/s12868-025-00966-4

Keywords: ketamine, essential tremor, motor outcomes, cognitive outcomes, inflammation, Lingo-1, neuroinflammation, pharmacology, precision medicine, neurodegenerative disorders.

DBS involves the surgical implantation of electrodes into specific areas of the brain, typically the subthalamic nucleus (STN) or globus pallidus internus (GPi), which deliver electrical pulses to modulate neural activity. While clinical benefits of DBS for tremor and rigidity have been well established, its effects on gait have been inconsistent. This variability stems in part from the complex neural circuits governing locomotion and the heterogeneous pathological processes within PD. To address these challenges, Fekri Azgomi and colleagues have pioneered computational models that decode the intricate neuronal dynamics underlying gait disturbances and simulate the impact of targeted stimulation.

The core innovation of their study lies in integrating patient-specific neurophysiological data—obtained through electrophysiological recordings and neuroimaging—with advanced computational algorithms. By applying biophysical models of neuronal populations, the researchers were able to replicate abnormal oscillatory patterns associated with gait dysfunction. These models then served as a virtual testbed to explore how different DBS parameter configurations influence network activity. Such in silico trials offer the advantage of rapid hypothesis testing without the risks and costs inherent to clinical experimentation.

One fundamental insight from their models relates to the phase and frequency of stimulation signals. Traditional DBS protocols typically adopt constant-frequency pulses, but the team’s simulations demonstrated that dynamically modulated stimulation, synchronized to the limb movement cycle, could restore more physiological oscillatory patterns. This time-locked approach appears to recalibrate defective neural circuitry involved in the initiation and execution of gait, enhancing the rhythmicity and stability of walking movements. The concept of closed-loop DBS, responding adaptively to ongoing neural feedback, aligns closely with these findings.

Moreover, the researchers uncovered that the spatial targeting of electrodes is crucial in maximizing gait improvement. Through detailed anatomical reconstructions and diffusion tensor imaging tractography, the models identified specific white matter pathways and subregions within the basal ganglia-thalamocortical circuitry that are key nodes in locomotor control. Tailoring stimulation to preferentially engage these pathways enhanced therapeutic benefits while minimizing side effects such as dyskinesias or speech disturbances, which often limit DBS tolerability.

Another notable achievement of this work is the incorporation of variability observed among individual patients into the models. Parkinson’s disease exhibits significant clinical heterogeneity, with gait impairments manifesting differently across patients depending on disease stage, genetic background, and comorbidities. By parameterizing the models with personalized electrophysiology and imaging data, the researchers created individualized virtual brains. This personalized modeling approach enables prediction of optimal stimulation settings for each patient, reducing the reliance on trial-and-error programming that currently prolongs DBS optimization in clinical practice.

Furthermore, this modeling framework sheds light on underlying disease mechanisms, offering a window into how pathological beta-band oscillations disrupt locomotor circuits. The excessive synchronization in the beta frequency range within STN and connected regions has long been implicated in motor deficits of PD. Through simulation, the authors demonstrated how carefully timed DBS pulses could desynchronize these pathological rhythms, thereby unmasking residual motor functionality. This mechanistic understanding bridges a critical gap between basic neuroscience and clinical intervention.

The implications of this research extend beyond gait improvement alone. The modeling strategy presents a versatile tool to investigate other complex PD symptoms such as freezing of gait—a transient inability to initiate steps—and postural instability. These phenomena are notoriously difficult to manage pharmacologically and often respond poorly to conventional stimulation. By simulating diverse neural conditions and stimulation paradigms, the platform serves as a powerful resource for designing novel DBS modalities to target these intractable symptoms.

Importantly, the study emphasizes the integration of multi-modal data streams encompassing electrophysiological signals, structural connectivity, and behavioral assessments. This holistic approach aligns with the emerging precision medicine paradigm, where therapy is customized based on detailed phenotypic and biological information. The researchers advocate for the deployment of their modeling tools alongside wearable sensors and real-time neural monitors to enable continuous adaptive DBS in ambulatory settings, thus overcoming limitations of static programming during clinic visits.

Despite these promising advances, challenges remain before routine clinical adoption can be realized. The computational complexity of the models demands significant processing power and sophisticated software interfaces accessible to clinicians. Ethical considerations also arise around the safe implementation of adaptive neurostimulation systems that autonomously alter brain activity. To address these issues, interdisciplinary collaborations bridging neuroscience, engineering, and clinical neurology will be essential in translating these findings into practical therapies.

Nonetheless, the potential benefits are profound. Personalized DBS optimized through computational modeling could revolutionize the therapeutic landscape for millions suffering from PD worldwide. Improvements in gait and mobility translate directly into enhanced independence and reduced caregiver burden, while minimizing stimulation-induced side effects improves overall quality of life. Such technology embodies the future of neuromodulation—intelligent, patient-specific, and deeply informed by neural science.

Beyond Parkinson’s disease, the modeling framework may find application in other movement disorders treated with DBS, such as dystonia and essential tremor. Moreover, lessons learned from dissecting gait circuits could inform neurorehabilitation strategies post-stroke or spinal cord injury. The convergence of computational neuroscience and clinical neurology exemplified in this work epitomizes a new era in brain health, where virtual trials expedite the discovery and deployment of safe, effective brain therapies.

In summary, the pioneering research by Fekri Azgomi, Louie, Bath, and colleagues presents a compelling vision for the future of DBS in Parkinson’s disease. By leveraging personalized neurophysiological data and sophisticated modeling techniques, they have charted a course toward optimizing stimulation protocols that directly target debilitating gait impairments. Their work not only advances fundamental understanding of basal ganglia circuitry but also sets the stage for transformative clinical innovations that promise to restore ambulatory function and improve lives on an unprecedented scale.

As the field progresses, future studies may expand the computational toolkit to incorporate additional biological complexities such as neurochemical dynamics, immune responses, and long-term plasticity effects induced by chronic stimulation. Integration with adaptive machine learning algorithms could further refine stimulation algorithms in real time. Combined clinical trials validating these approaches will be critical to definitively prove safety and efficacy, paving the way for regulatory approvals and broad dissemination.

What remains clear is the immense promise harnessed at the intersection of neuroengineering and precision medicine. The quest to restore gait in Parkinson’s disease illustrates how bridging fundamental neuroscience with cutting-edge technology can unravel the complexity of brain disorders. Personalized DBS, informed by detailed computational models, may soon transform what was once a standard palliation into a dynamic, fine-tuned intervention that empowers patients to walk steadily again, reclaiming mobility and hope.

Subject of Research: Parkinson’s disease gait dysfunction and optimization of deep brain stimulation through personalized neurophysiological modeling.

Article Title: Modeling and optimizing deep brain stimulation to enhance gait in Parkinson’s disease: personalized treatment with neurophysiological insights.

Article References:
Fekri Azgomi, H., Louie, K.H., Bath, J.E. et al. Modeling and optimizing deep brain stimulation to enhance gait in Parkinson’s disease: personalized treatment with neurophysiological insights. npj Parkinsons Dis. 11, 173 (2025). https://doi.org/10.1038/s41531-025-00990-5

Image Credits: AI Generated